down arrow

Allogene Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0197701065
USD
1.44
0.1 (7.46%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.421.50

52 Week

0.863.78
Valuation
Technical
Day's Volume

CASH

325.66 k

Shareholding (Mar 2025)

FII

19.13%

Held by 107 FIIs

DII

17.4%

Held by 62 DIIs

Promoter

24.59%

How big is Allogene Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Allogene Therapeutics, Inc. has a market capitalization of 284.35 million, with net sales of 0.00 million and a net profit of -252.32 million over the latest four quarters. The company reported shareholder's funds of 422.18 million and total assets of 548.71 million as of Dec'24.

Market Cap: As of Jun 18, Allogene Therapeutics, Inc. has a market capitalization of 284.35 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Allogene Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -252.32 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 422.18 million and total assets of 548.71 million.

Read More

What does Allogene Therapeutics, Inc. do?

22-Jun-2025

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company developing allogeneic T cell therapies for cancer treatment. It has a market cap of $284.35 million and reported a net profit loss of $60 million as of March 2025.

Overview: <BR>Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company focused on developing and commercializing allogeneic T cell therapies for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -60 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 284.35 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.71 <BR>Return on Equity: -61.39% <BR>Price to Book: 0.74<BR><BR>Contact Details: <BR>Address: 210 E Grand Ave, SOUTH SAN FRANCISCO CA 94080-4811 <BR>Tel: 1 650 4572700 <BR>Website: http://www.allogene.com/

Read More

Who are in the management team of Allogene Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Allogene Therapeutics, Inc. includes Dr. Arie Belldegrun (Executive Chairman), Dr. David Chang (President and CEO), and Mr. Joshua Kazam (Co-Founder). The Board of Directors also features independent members such as Mr. David Bonderman and Dr. Franz Humer.

As of March 2022, the management team of Allogene Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Arie Belldegrun: Executive Chairman of the Board<BR>- Dr. David Chang: President, Chief Executive Officer, Co-Founder, Director<BR>- Mr. Joshua Kazam: Co-Founder, Director<BR><BR>Additionally, the Board of Directors features several independent directors, including Mr. David Bonderman, Mr. John DeYoung, Dr. Franz Humer, Ms. Deborah Messemer, and Mr. Todd Sisitsky.

Read More

Is Allogene Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 4, 2022, Allogene Therapeutics, Inc. is considered overvalued due to significant financial losses, reflected in metrics like a price-to-book value of 0.81, a negative P/E ratio of -1.2018, and a year-to-date return of -42.72%, indicating a deterioration in its financial standing compared to peers and the S&P 500.

As of 4 May 2022, the valuation grade for Allogene Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued given its negative performance metrics, including a price-to-book value of 0.81 and an EV to EBITDA of -0.16. Additionally, the return on capital employed (ROCE) stands at a staggering -224.08%, and the return on equity (ROE) is at -61.39%, reflecting substantial losses.<BR><BR>In comparison to its peers, Allogene Therapeutics, Inc. shows a P/E ratio of -1.2018, while Enliven Therapeutics, Inc. has a P/E of -11.1774, and Wave Life Sciences Ltd. is at -9.0427, highlighting that Allogene is not alone in its struggles but still underperforms relative to its peers. The company's stock has significantly lagged behind the S&P 500, with a year-to-date return of -42.72% compared to the index's 2.44%. Overall, Allogene Therapeutics, Inc. appears to be overvalued in the current market environment.

Read More

Is Allogene Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 18, 2025, Allogene Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, having returned 3.42% over the past week and 11.01% over the past month, but is down 43.19% year-to-date compared to the S&P 500's 12.22% gain.

As of 18 August 2025, the technical trend for Allogene Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals: the MACD is mildly bullish on both weekly and monthly time frames, while the moving averages indicate a mildly bearish trend on the daily. The Bollinger Bands suggest a bullish outlook weekly but a mildly bearish one monthly. Additionally, the KST is mildly bullish weekly but bearish monthly, and the Dow Theory indicates a mildly bearish trend weekly with no trend monthly.<BR><BR>In terms of performance, the stock has returned 3.42% over the past week and 11.01% over the past month, outperforming the S&P 500, which returned 1.05% and 2.33% respectively. However, the year-to-date return is -43.19%, significantly underperforming the S&P 500's 12.22%. Over the longer term, the stock has seen substantial declines, with a 5-year return of -96.82% compared to the S&P 500's 96.61%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 253 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.77

stock-summary
Return on Equity

-64.95%

stock-summary
Price to Book

0.73

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-51 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.57%
0%
28.57%
6 Months
6.67%
0%
6.67%
1 Year
-37.8%
0%
-37.8%
2 Years
-42.86%
0%
-42.86%
3 Years
-84.78%
0%
-84.78%
4 Years
-91.83%
0%
-91.83%
5 Years
-95.54%
0%
-95.54%

Allogene Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Allogene Therapeutics, Inc. technically bullish or bearish?

As of 18 August 2025, the technical trend for Allogene Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals: the MACD is mildly bullish on both weekly and monthly time frames, while the moving averages indicate a mildly bearish trend on the daily. The Bollinger Bands suggest a bullish outlook weekly but a mildly bearish one monthly. Additionally, the KST is mildly bullish weekly but bearish monthly, and the Dow Theory indicates a mildly bearish trend weekly with no trend monthly. In terms of performance, the stock has returned 3.42% over the past week and 11.01% over the past month, outperforming the S&P 500, which returned 1.05% and 2.33% respectively. However, the year-to-date return is -43.19%, significantly underperforming the S&P 500's 12.22%. Over the longer term, the stock has seen substantial declines, with a ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-0.06%
EBIT to Interest (avg)
-269.24
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.81
EV to EBIT
-0.15
EV to EBITDA
-0.16
EV to Capital Employed
0.34
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-224.08%
ROE (Latest)
-61.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 55 Schemes (38.85%)

Foreign Institutions

Held by 107 Foreign Institutions (19.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 14.74% vs 0.33% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-51.30",
          "val2": "-62.10",
          "chgp": "17.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-50.90",
          "val2": "-59.70",
          "chgp": "14.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 21.30% vs 3.85% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-243.80",
          "val2": "-300.30",
          "chgp": "18.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.70",
          "val2": "-13.20",
          "chgp": "-18.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-257.60",
          "val2": "-327.30",
          "chgp": "21.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11,703,727.30%",
          "val2": "-3,310,442.10%",
          "chgp": "-8,39,328.52%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-51.30
-62.10
17.39%
Interest
0.30
0.10
200.00%
Exceptional Items
-2.40
0.00
Consolidate Net Profit
-50.90
-59.70
14.74%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 14.74% vs 0.33% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-243.80
-300.30
18.81%
Interest
0.20
0.00
Exceptional Items
-15.70
-13.20
-18.94%
Consolidate Net Profit
-257.60
-327.30
21.30%
Operating Profit Margin (Excl OI)
-11,703,727.30%
-3,310,442.10%
-8,39,328.52%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 21.30% vs 3.85% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Allogene Therapeutics, Inc. stock-summary
stock-summary
Allogene Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.
Company Coordinates stock-summary
Company Details
210 E Grand Ave , SOUTH SAN FRANCISCO CA : 94080-4811
stock-summary
Tel: 1 650 4572700
stock-summary
http://www.allogene.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."